Kuria Therapeutics

Kuria Therapeutics is developing a novel topical Nrf2 activator for important diseases of the eye. Our lead program (KTX-1161) targets the corneal endothelium, where there is strong biologic evidence that activation of Nrf2 can treat and prevent diseases with high unmet medical need. KTX-1161 is currently in preclinical development for the treatment of Fuchs' dystrophy and prevention of corneal endothelial damage associated with cataract surgery.